Association of tamoxifen use and reduced cardiovascular events among asian females with breast cancer

Tsung Lin Yang, Tao Cheng Wu, Chin Chou Huang, Po Hsun Huang, Chia Min Chung, Shing Jong Lin, Jaw Wen Chen, Wan Leong Chan, Chia Hung Chiang, Hsin Bang Leu

研究成果: 雜誌貢獻文章同行評審

15 引文 斯高帕斯(Scopus)


Background: Tamoxifen is used for breast cancer treatment and has been reported to be beneficial for the cardiovascular system, but it is unclear whether tamoxifen exhibits a favorable cardiovascular effect in Asian patients. Methods and Results: From January, 1998 to December, 2006, a breast cancer cohort study was conducted using the Taiwan National Health Insurance database. Patients were divided according to whether tamoxifen was used. Study endpoints were occurrence of acute myocardial infarction (AMI), ischemic or hemorrhagic stroke and total cardiovascular events. A total of 3,690 female subjects were enrolled (mean age 50.1±11.3), 2,056 of whom received tamoxifen and 1,634 did not. During a mean follow-up of 6.9 years, the tamoxifen group had a significantly lower incidence of AMI (0.15% vs. 0.67%, P=0.008), ischemic stroke (1.99% vs. 3.30%, P=0.008), hemorrhagic stroke (0.15% vs. 0.55%, P=0.029), and total cardiovascular events (2.24% vs. 4.16%, P<0.001) than the non-exposed group. After adjusting for comorbidities, tamoxifen was independently associated with a reduced risk of myocardial infarction (hazard ratio [HR] 0.22; 95% confidence interval [CI] 0.07-0.70, ischemic stroke (HR 0.52; 95% CI 0.35-0.78), hemorrhagic stroke (HR 0.25; 95% CI 0.07-0.92), and total cardiovascular events (HR 0.54; 95% CI 0.37-0.78). Conclusions: In Asian female breast cancer patients, tamoxifen use was associated with reduced risks of AMI, ischemic, hemorrhagic stroke and total cardiovascular events.
頁(從 - 到)135-140
期刊Circulation Journal
出版狀態已發佈 - 2014

ASJC Scopus subject areas

  • 心臟病學與心血管醫學


深入研究「Association of tamoxifen use and reduced cardiovascular events among asian females with breast cancer」主題。共同形成了獨特的指紋。